opacin-neo and prado: personalized neoadjuvant io for melanoma based on pathologic response
Published 11 months ago • 71 plays • Length 1:54Download video MP4
Download video MP3
Similar videos
-
2:33
opacin-neo & prado 3-year results in stage iii melanoma: personalized neoadjuvant io benefits
-
4:02
prado: personalized response-driven surgery and adjuvant therapy in stage iii melanoma
-
2:24
prado: personalized response-driven therapy in resectable stage iii melanoma
-
1:30
omission of adjuvant therapy and tlnd in melanoma: insights from opacin-neo, prado, and nadina
-
1:39
opacin and opacin-neo: neoadjuvant immunotherapy for advanced melanoma
-
1:27
emerging trials in melanoma: swog s1801, opacin-neo and prado
-
2:53
opacin-neo: tmb and ifn-γ identified as biomarkers of pathologic response in melanoma
-
1:22
the personalization of neoadjuvant immunotherapy in stage iii melanoma
-
3:19
donimi: neoadjuvant domatinostat in patients with melanoma based on ifn-γ signatures
-
2:12
omitting total lymph node dissection and adjuvant therapy in melanoma
-
3:15
optimal neoadjuvant io in resectable stage iii melanoma: interferon gamma signature analysis
-
1:16
neoadjuvant ipi nivo in stage iii melanoma: updates from opacin & opacin-neo
-
27:18
adjuvant and neoadjuvant dilemmas
-
2:52
opacin-neo trial rfs and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma
-
3:28
neoadjuvant therapy in melanoma: the prado trial - 2022 program: melanoma video library
-
0:37
swog s1801: pathologic response in neoadjuvant-adjuvant vs. adjuvant pembro for resectable melanoma
-
2:10
neoadjuvant therapy for melanoma
-
24:47
adjuvant and neoadjuvant therapy for melanoma weber 2021
-
3:44
neoadjuvant approaches in melanoma